Month: February 2011


Will Australian Pharma ever be the same again?

Melbourne, 22nd February 2011 - The Australian pharmaceutical industry landscape is set to dramatically alter as a result of government changes to the Pharmaceutical Benefits Scheme (PBS), suggests independent market analyst, Datamonitor. Datamonitor’s outlook for the future includes withdrawn products, a struggling generics sector and wholesaler reorganization, as PBS reforms take effect. Erin Brady, Australian…

23 Feb 2011, by Test1 Test1


Breast cancer cases on the rise in Japan

Melbourne, 18th February 2011. The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13% over the next decade, finds independent healthcare analyst, Datamonitor.* However, in Japan, breast cancer incidence rates will rise by approximately 24% to 2019 to reach 56,400 cases, compared to 45,600…

18 Feb 2011, by Test1 Test1


Diabetes pipeline cannot reverse cardiovascular and metabolic market decline

Melbourne, 10th February 2011 - Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, finds independent market analyst Datamonitor.* Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets** will peak in 2011 and then begin to decline, with total sales falling from $105bn in…

10 Feb 2011, by Test1 Test1


Can India become a biosimilar powerhouse?

Melbourne, 8th February 2011 - Indian manufacturers are ideally placed to capitalise on the growing biosimilars market, according to independent market analyst Datamonitor. Although the biosimilars market is in its infancy, Datamonitor research suggests that Indian manufacturers are well positioned to capitalise on the future growth of this market both domestically and internationally. Alistair Sinclair,…

8 Feb 2011, by Test1 Test1